Nutritional support for cancer cachexia: A systematic review and meta-analysis of randomized controlled trials.

Clin Nutr ESPENJul 20, 2026 (epub)
Clinical ResearchOncology (Medical)

Lucas Porto Santos, Bruno Gualano, Miriam López-Teros et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of nutritional support on cancer cachexia in adults, analyzing 32 randomized controlled trials. The study found that nutritional support led to modest increases in body weight (MD: 1.43 kg) and fat-free mass (MD: 1.11 kg), but did not significantly improve handgrip strength, quality of life, or appetite.

Key findings

  • Nutritional support resulted in a mean increase in body weight of 1.43 kg (95% CI: 0.55-2.31 kg).
  • Fat-free mass increased by a mean of 1.11 kg (95% CI: 0.16-2.05 kg) with nutritional support.
  • No significant effects were observed on handgrip strength, quality of life, or appetite.

Why it matters

Understanding the limited benefits of nutritional support in cancer cachexia is crucial for clinicians managing this complex syndrome. It highlights the need for comprehensive treatment strategies beyond nutritional interventions alone.

What to keep in mind

The evidence was limited by a predominant high risk of bias across the included studies.

Source

Published in Clin Nutr ESPEN. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.